Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Dalcinonacog alfa LA by Gyre Therapeutics for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Dalcinonacog alfa LA is under clinical development by Gyre Therapeutics and currently in Phase II for Hemophilia B (Factor IX...